Skip to main content
Top

14-04-2024 | Myocardial Infarction | Invited Review Article

Importance of reassessment to identify trajectories of chronic transition of clinical indicators in post-myocardial infarction management

Authors: Goro Yoshioka, Atsushi Tanaka, Shinjo Sonoda, Tetsuya Kaneko, Hiroshi Hongo, Kensuke Yokoi, Masahiro Natsuaki, Koichi Node

Published in: Cardiovascular Intervention and Therapeutics

Login to get access

Abstract

Despite advances in multidisciplinary acute care for myocardial infarction (MI), the clinical need to manage heart failure and elevated mortality risks in the remote phase of MI remains unmet. Various prognostic models have been established using clinical indicators obtained during the acute phase of MI; however, most of these indicators also show chronic changes in the post-MI phase. Although relevant guidelines recommend follow-up assessments of some clinical indicators in the chronic phase, systematic reassessment has not yet been fully established and implemented in a real-world clinical setting. Therefore, clinical evidence of the impact of such chronic transitions on the post-MI prognosis is lacking. We speculate that post-MI reassessment of key clinical indicators and the impact of their chronic transition patterns on long-term prognoses can improve the quality of post-MI risk stratification and help identify residual risk factors. Several recent studies have investigated the impact of the chronic transition of some clinical indicators, such as serum albumin level, mitral regurgitation, and left-ventricular dysfunction, on post-MI prognosis. Interestingly, even in MI survivors with these indicators within their respective normal ranges in the acute phase of MI, chronic transition to an abnormal range was associated with worsening cardiovascular outcomes. On the basis of these recent insights, we discuss the clinical significance of post-MI reassessment to identify the trajectories of several clinical indicators and elucidate the potential residual risk factors affecting adverse outcomes in MI survivors.
Literature
1.
go back to reference Puymirat E, Simon T, Steg PG, et al. Association of changes in clinical characteristics and management with improvement in survival among patients with ST-elevation myocardial infarction. JAMA. 2012;308:998–1006.PubMedCrossRef Puymirat E, Simon T, Steg PG, et al. Association of changes in clinical characteristics and management with improvement in survival among patients with ST-elevation myocardial infarction. JAMA. 2012;308:998–1006.PubMedCrossRef
2.
go back to reference Krumholz HM, Wang Y, Chen J, et al. Reduction in acute myocardial infarction mortality in the United States: risk-standardized mortality rates from 1995–2006. JAMA. 2009;302:767–73.PubMedPubMedCentralCrossRef Krumholz HM, Wang Y, Chen J, et al. Reduction in acute myocardial infarction mortality in the United States: risk-standardized mortality rates from 1995–2006. JAMA. 2009;302:767–73.PubMedPubMedCentralCrossRef
3.
go back to reference Yeh RW, Sidney S, Chandra M, Sorel M, Selby JV, Go AS. Population trends in the incidence and outcomes of acute myocardial infarction. N Engl J Med. 2010;362:2155–65.PubMedCrossRef Yeh RW, Sidney S, Chandra M, Sorel M, Selby JV, Go AS. Population trends in the incidence and outcomes of acute myocardial infarction. N Engl J Med. 2010;362:2155–65.PubMedCrossRef
4.
go back to reference Natsuaki M, Sonoda S, Yoshioka G, et al. Antiplatelet therapy after percutaneous coronary intervention: current status and future perspectives. Cardiovasc Interv Ther. 2022;37:255–63.PubMedCrossRef Natsuaki M, Sonoda S, Yoshioka G, et al. Antiplatelet therapy after percutaneous coronary intervention: current status and future perspectives. Cardiovasc Interv Ther. 2022;37:255–63.PubMedCrossRef
5.
go back to reference Ozaki Y, Hara H, Onuma Y, et al. CVIT expert consensus document on primary percutaneous coronary intervention (PCI) for acute myocardial infarction (AMI) update 2022. Cardiovasc Interv Ther. 2022;37:1–34.PubMedPubMedCentralCrossRef Ozaki Y, Hara H, Onuma Y, et al. CVIT expert consensus document on primary percutaneous coronary intervention (PCI) for acute myocardial infarction (AMI) update 2022. Cardiovasc Interv Ther. 2022;37:1–34.PubMedPubMedCentralCrossRef
6.
go back to reference Kuramitsu S, Sonoda S, Ando K, et al. Drug-eluting stent thrombosis: current and future perspectives. Cardiovasc Interv Ther. 2021;36:158–68.PubMedCrossRef Kuramitsu S, Sonoda S, Ando K, et al. Drug-eluting stent thrombosis: current and future perspectives. Cardiovasc Interv Ther. 2021;36:158–68.PubMedCrossRef
7.
go back to reference Ng VG, Lansky AJ, Meller S, et al. The prognostic importance of left ventricular function in patients with ST-segment elevation myocardial infarction: the HORIZONS-AMI trial. Eur Heart J Acute Cardiovasc Care. 2014;3:67–77.PubMedPubMedCentralCrossRef Ng VG, Lansky AJ, Meller S, et al. The prognostic importance of left ventricular function in patients with ST-segment elevation myocardial infarction: the HORIZONS-AMI trial. Eur Heart J Acute Cardiovasc Care. 2014;3:67–77.PubMedPubMedCentralCrossRef
8.
go back to reference Granger CB, Goldberg RJ, Dabbous O, et al. Predictors of hospital mortality in the global registry of acute coronary events. Arch Intern Med. 2003;163:2345–53.PubMedCrossRef Granger CB, Goldberg RJ, Dabbous O, et al. Predictors of hospital mortality in the global registry of acute coronary events. Arch Intern Med. 2003;163:2345–53.PubMedCrossRef
9.
go back to reference Morrow DA, Antman EM, Parsons L, et al. Application of the TIMI risk score for ST-elevation MI in the National Registry of Myocardial Infarction 3. JAMA. 2001;286:1356–9.PubMedCrossRef Morrow DA, Antman EM, Parsons L, et al. Application of the TIMI risk score for ST-elevation MI in the National Registry of Myocardial Infarction 3. JAMA. 2001;286:1356–9.PubMedCrossRef
10.
go back to reference Kimura K, Kimura T, Ishihara M, et al. JCS 2018 guideline on diagnosis and treatment of acute coronary syndrome. Circ J. 2019;83:1085–196.PubMedCrossRef Kimura K, Kimura T, Ishihara M, et al. JCS 2018 guideline on diagnosis and treatment of acute coronary syndrome. Circ J. 2019;83:1085–196.PubMedCrossRef
11.
go back to reference Ibanez B, James S, Agewall S, et al. 2017 ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation: the task force for the management of acute myocardial infarction in patients presenting with ST-segment elevation of the European Society of Cardiology (ESC). Eur Heart J. 2018;39:119–77.PubMedCrossRef Ibanez B, James S, Agewall S, et al. 2017 ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation: the task force for the management of acute myocardial infarction in patients presenting with ST-segment elevation of the European Society of Cardiology (ESC). Eur Heart J. 2018;39:119–77.PubMedCrossRef
12.
go back to reference Byrne RA, Rossello X, Coughlan JJ, et al. 2023 ESC Guidelines for the management of acute coronary syndromes. Eur Heart J. 2023;44:3720–826.PubMedCrossRef Byrne RA, Rossello X, Coughlan JJ, et al. 2023 ESC Guidelines for the management of acute coronary syndromes. Eur Heart J. 2023;44:3720–826.PubMedCrossRef
13.
go back to reference Shimizu A. What are the most useful predictors of cardiac mortality in patients post myocardial infarction? Circ J. 2013;77:319–20.PubMedCrossRef Shimizu A. What are the most useful predictors of cardiac mortality in patients post myocardial infarction? Circ J. 2013;77:319–20.PubMedCrossRef
14.
go back to reference Nienhuis MB, Ottervanger JP, Dambrink JH, et al. Comparative predictive value of infarct location, peak CK, and ejection fraction after primary PCI for ST elevation myocardial infarction. Coron Artery Dis. 2009;20:9–14.PubMedCrossRef Nienhuis MB, Ottervanger JP, Dambrink JH, et al. Comparative predictive value of infarct location, peak CK, and ejection fraction after primary PCI for ST elevation myocardial infarction. Coron Artery Dis. 2009;20:9–14.PubMedCrossRef
15.
go back to reference Brooks GC, Lee BK, Rao R, et al. Predicting persistent left ventricular dysfunction following myocardial infarction: the PREDICTS study. J Am Coll Cardiol. 2016;67:1186–96.PubMedPubMedCentralCrossRef Brooks GC, Lee BK, Rao R, et al. Predicting persistent left ventricular dysfunction following myocardial infarction: the PREDICTS study. J Am Coll Cardiol. 2016;67:1186–96.PubMedPubMedCentralCrossRef
16.
go back to reference Chew DS, Wilton SB, Kavanagh K, Southern DA, Tan-Mesiatowsky LE, Exner DV. Left ventricular ejection fraction reassessment post-myocardial infarction: current clinical practice and determinants of adverse remodeling. Am Heart J. 2018;198:91–6.PubMedCrossRef Chew DS, Wilton SB, Kavanagh K, Southern DA, Tan-Mesiatowsky LE, Exner DV. Left ventricular ejection fraction reassessment post-myocardial infarction: current clinical practice and determinants of adverse remodeling. Am Heart J. 2018;198:91–6.PubMedCrossRef
17.
go back to reference Gajarsa JJ, Kloner RA. Left ventricular remodeling in the post-infarction heart: a review of cellular, molecular mechanisms, and therapeutic modalities. Heart Fail Rev. 2011;16:13–21.PubMedCrossRef Gajarsa JJ, Kloner RA. Left ventricular remodeling in the post-infarction heart: a review of cellular, molecular mechanisms, and therapeutic modalities. Heart Fail Rev. 2011;16:13–21.PubMedCrossRef
18.
go back to reference Kuga K, Yamasaki H, Hattori A, et al. Prognosis of myocardial infarction with left ventricular dysfunction in the coronary revascularization era. Subanalysis of the Japanese Coronary Artery Disease (JCAD) Study. Circ J. 2014;78:2483–91.PubMedCrossRef Kuga K, Yamasaki H, Hattori A, et al. Prognosis of myocardial infarction with left ventricular dysfunction in the coronary revascularization era. Subanalysis of the Japanese Coronary Artery Disease (JCAD) Study. Circ J. 2014;78:2483–91.PubMedCrossRef
19.
go back to reference De Luca G, Suryapranata H, Ottervanger JP, Antman EM. Time delay to treatment and mortality in primary angioplasty for acute myocardial infarction: every minute of delay counts. Circulation. 2004;109:1223–5.PubMedCrossRef De Luca G, Suryapranata H, Ottervanger JP, Antman EM. Time delay to treatment and mortality in primary angioplasty for acute myocardial infarction: every minute of delay counts. Circulation. 2004;109:1223–5.PubMedCrossRef
20.
go back to reference Bolognese L, Cerisano G. Early predictors of left ventricular remodeling after acute myocardial infarction. Am Heart J. 1999;138:S79-83.PubMedCrossRef Bolognese L, Cerisano G. Early predictors of left ventricular remodeling after acute myocardial infarction. Am Heart J. 1999;138:S79-83.PubMedCrossRef
21.
go back to reference Cohn JN, Ferrari R, Sharpe N. Cardiac remodeling–concepts and clinical implications: a consensus paper from an international forum on cardiac remodelling. Behalf of an international forum on cardiac remodeling. J Am Coll Cardiol. 2000;35:569–82.PubMedCrossRef Cohn JN, Ferrari R, Sharpe N. Cardiac remodeling–concepts and clinical implications: a consensus paper from an international forum on cardiac remodelling. Behalf of an international forum on cardiac remodeling. J Am Coll Cardiol. 2000;35:569–82.PubMedCrossRef
22.
go back to reference Wilton SB, Bennett MT, Parkash R, et al. Variability in reassessment of left ventricular ejection fraction after myocardial infarction in the acute myocardial infarction quality assurance canada study. JAMA Netw Open. 2021;4:e2136830.PubMedPubMedCentralCrossRef Wilton SB, Bennett MT, Parkash R, et al. Variability in reassessment of left ventricular ejection fraction after myocardial infarction in the acute myocardial infarction quality assurance canada study. JAMA Netw Open. 2021;4:e2136830.PubMedPubMedCentralCrossRef
23.
go back to reference Yoshioka G, Tanaka A, Watanabe N, et al. Prognostic impact of incident left ventricular systolic dysfunction after myocardial infarction. Front Cardiovasc Med. 2022;9:1009691.PubMedPubMedCentralCrossRef Yoshioka G, Tanaka A, Watanabe N, et al. Prognostic impact of incident left ventricular systolic dysfunction after myocardial infarction. Front Cardiovasc Med. 2022;9:1009691.PubMedPubMedCentralCrossRef
24.
go back to reference Dargie HJ. Effect of carvedilol on outcome after myocardial infarction in patients with left-ventricular dysfunction: the CAPRICORN randomised trial. Lancet. 2001;357:1385–90.PubMedCrossRef Dargie HJ. Effect of carvedilol on outcome after myocardial infarction in patients with left-ventricular dysfunction: the CAPRICORN randomised trial. Lancet. 2001;357:1385–90.PubMedCrossRef
25.
go back to reference Miller CD, Roe MT, Mulgund J, et al. Impact of acute beta-blocker therapy for patients with non-ST-segment elevation myocardial infarction. Am J Med. 2007;120:685–92.PubMedCrossRef Miller CD, Roe MT, Mulgund J, et al. Impact of acute beta-blocker therapy for patients with non-ST-segment elevation myocardial infarction. Am J Med. 2007;120:685–92.PubMedCrossRef
26.
go back to reference Bangalore S, Makani H, Radford M, et al. Clinical outcomes with β-blockers for myocardial infarction: a meta-analysis of randomized trials. Am J Med. 2014;127:939–53.PubMedCrossRef Bangalore S, Makani H, Radford M, et al. Clinical outcomes with β-blockers for myocardial infarction: a meta-analysis of randomized trials. Am J Med. 2014;127:939–53.PubMedCrossRef
27.
go back to reference Singh K, Hibbert B, Singh B, et al. Meta-analysis of admission hyperglycaemia in acute myocardial infarction patients treated with primary angioplasty: a cause or a marker of mortality? Eur Heart J Cardiovasc Pharmacother. 2015;1:220–8.PubMedCrossRef Singh K, Hibbert B, Singh B, et al. Meta-analysis of admission hyperglycaemia in acute myocardial infarction patients treated with primary angioplasty: a cause or a marker of mortality? Eur Heart J Cardiovasc Pharmacother. 2015;1:220–8.PubMedCrossRef
28.
go back to reference Pfeffer MA, Braunwald E, Moyé LA, et al. Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. Results of the survival and ventricular enlargement trial. The SAVE Investigators. N Engl J Med. 1992;327:669–77.PubMedCrossRef Pfeffer MA, Braunwald E, Moyé LA, et al. Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. Results of the survival and ventricular enlargement trial. The SAVE Investigators. N Engl J Med. 1992;327:669–77.PubMedCrossRef
29.
go back to reference Huikuri HV, Castellanos A, Myerburg RJ. Sudden death due to cardiac arrhythmias. N Engl J Med. 2001;345:1473–82.PubMedCrossRef Huikuri HV, Castellanos A, Myerburg RJ. Sudden death due to cardiac arrhythmias. N Engl J Med. 2001;345:1473–82.PubMedCrossRef
30.
go back to reference Bardy GH, Lee KL, Mark DB, et al. Amiodarone or an implantable cardioverter-defibrillator for congestive heart failure. N Engl J Med. 2005;352:225–37.PubMedCrossRef Bardy GH, Lee KL, Mark DB, et al. Amiodarone or an implantable cardioverter-defibrillator for congestive heart failure. N Engl J Med. 2005;352:225–37.PubMedCrossRef
31.
go back to reference Buxton AE, Lee KL, Fisher JD, Josephson ME, Prystowsky EN, Hafley G. A randomized study of the prevention of sudden death in patients with coronary artery disease. Multicenter Unsustained Tachycardia Trial Investigators. N Engl J Med. 1999;341:1882–90.PubMedCrossRef Buxton AE, Lee KL, Fisher JD, Josephson ME, Prystowsky EN, Hafley G. A randomized study of the prevention of sudden death in patients with coronary artery disease. Multicenter Unsustained Tachycardia Trial Investigators. N Engl J Med. 1999;341:1882–90.PubMedCrossRef
33.
go back to reference Bursi F, Enriquez-Sarano M, Nkomo VT, et al. Heart failure and death after myocardial infarction in the community: the emerging role of mitral regurgitation. Circulation. 2005;111:295–301.PubMedCrossRef Bursi F, Enriquez-Sarano M, Nkomo VT, et al. Heart failure and death after myocardial infarction in the community: the emerging role of mitral regurgitation. Circulation. 2005;111:295–301.PubMedCrossRef
34.
go back to reference Grigioni F, Enriquez-Sarano M, Zehr KJ, Bailey KR, Tajik AJ. Ischemic mitral regurgitation: long-term outcome and prognostic implications with quantitative Doppler assessment. Circulation. 2001;103:1759–64.PubMedCrossRef Grigioni F, Enriquez-Sarano M, Zehr KJ, Bailey KR, Tajik AJ. Ischemic mitral regurgitation: long-term outcome and prognostic implications with quantitative Doppler assessment. Circulation. 2001;103:1759–64.PubMedCrossRef
35.
36.
go back to reference Kaul S, Spotnitz WD, Glasheen WP, Touchstone DA. Mechanism of ischemic mitral regurgitation. An experimental evaluation. Circulation. 1991;84:2167–80.PubMedCrossRef Kaul S, Spotnitz WD, Glasheen WP, Touchstone DA. Mechanism of ischemic mitral regurgitation. An experimental evaluation. Circulation. 1991;84:2167–80.PubMedCrossRef
37.
go back to reference Otsuji Y, Handschumacher MD, Schwammenthal E, et al. Insights from three-dimensional echocardiography into the mechanism of functional mitral regurgitation: direct in vivo demonstration of altered leaflet tethering geometry. Circulation. 1997;96:1999–2008.PubMedCrossRef Otsuji Y, Handschumacher MD, Schwammenthal E, et al. Insights from three-dimensional echocardiography into the mechanism of functional mitral regurgitation: direct in vivo demonstration of altered leaflet tethering geometry. Circulation. 1997;96:1999–2008.PubMedCrossRef
38.
go back to reference Nishino S, Watanabe N, Kimura T, Kuriyama N, Shibata Y. Acute versus chronic ischemic mitral regurgitation: an echocardiographic study of anatomy and physiology. Circ Cardiovasc Imaging. 2018;11:e007028.PubMedCrossRef Nishino S, Watanabe N, Kimura T, Kuriyama N, Shibata Y. Acute versus chronic ischemic mitral regurgitation: an echocardiographic study of anatomy and physiology. Circ Cardiovasc Imaging. 2018;11:e007028.PubMedCrossRef
39.
go back to reference Kimura T, Roger VL, Watanabe N, et al. The unique mechanism of functional mitral regurgitation in acute myocardial infarction: a prospective dynamic 4D quantitative echocardiographic study. Eur Heart J Cardiovasc Imaging. 2019;20:396–406.PubMedCrossRef Kimura T, Roger VL, Watanabe N, et al. The unique mechanism of functional mitral regurgitation in acute myocardial infarction: a prospective dynamic 4D quantitative echocardiographic study. Eur Heart J Cardiovasc Imaging. 2019;20:396–406.PubMedCrossRef
41.
go back to reference Funaro S, La Torre G, Madonna M, et al. Incidence, determinants, and prognostic value of reverse left ventricular remodelling after primary percutaneous coronary intervention: results of the Acute Myocardial Infarction Contrast Imaging (AMICI) multicenter study. Eur Heart J. 2009;30:566–75.PubMedCrossRef Funaro S, La Torre G, Madonna M, et al. Incidence, determinants, and prognostic value of reverse left ventricular remodelling after primary percutaneous coronary intervention: results of the Acute Myocardial Infarction Contrast Imaging (AMICI) multicenter study. Eur Heart J. 2009;30:566–75.PubMedCrossRef
42.
go back to reference Nishino S, Watanabe N, Kimura T, et al. The course of ischemic mitral regurgitation in acute myocardial infarction after primary percutaneous coronary intervention: from emergency room to long-term follow-up. Circ Cardiovasc Imaging. 2016;9:e004841.PubMedCrossRef Nishino S, Watanabe N, Kimura T, et al. The course of ischemic mitral regurgitation in acute myocardial infarction after primary percutaneous coronary intervention: from emergency room to long-term follow-up. Circ Cardiovasc Imaging. 2016;9:e004841.PubMedCrossRef
43.
go back to reference Izumi C, Eishi K, Ashihara K, et al. JCS/JSCS/JATS/JSVS 2020 guidelines on the management of valvular heart disease. Circ J. 2020;84:2037–119.PubMedCrossRef Izumi C, Eishi K, Ashihara K, et al. JCS/JSCS/JATS/JSVS 2020 guidelines on the management of valvular heart disease. Circ J. 2020;84:2037–119.PubMedCrossRef
44.
go back to reference Mirabel M, Iung B, Baron G, et al. What are the characteristics of patients with severe, symptomatic, mitral regurgitation who are denied surgery? Eur Heart J. 2007;28:1358–65.PubMedCrossRef Mirabel M, Iung B, Baron G, et al. What are the characteristics of patients with severe, symptomatic, mitral regurgitation who are denied surgery? Eur Heart J. 2007;28:1358–65.PubMedCrossRef
45.
go back to reference Kataoka A, Watanabe Y. MitraClip: a review of its current status and future perspectives. Cardiovasc Interv Ther. 2023;38:28–38.PubMedCrossRef Kataoka A, Watanabe Y. MitraClip: a review of its current status and future perspectives. Cardiovasc Interv Ther. 2023;38:28–38.PubMedCrossRef
46.
go back to reference Fanali G, di Masi A, Trezza V, Marino M, Fasano M, Ascenzi P. Human serum albumin: from bench to bedside. Mol Aspects Med. 2012;33:209–90.PubMedCrossRef Fanali G, di Masi A, Trezza V, Marino M, Fasano M, Ascenzi P. Human serum albumin: from bench to bedside. Mol Aspects Med. 2012;33:209–90.PubMedCrossRef
47.
go back to reference Caraceni P, Domenicali M, Tovoli A, et al. Clinical indications for the albumin use: still a controversial issue. Eur J Intern Med. 2013;24:721–8.PubMedCrossRef Caraceni P, Domenicali M, Tovoli A, et al. Clinical indications for the albumin use: still a controversial issue. Eur J Intern Med. 2013;24:721–8.PubMedCrossRef
48.
49.
50.
go back to reference Mukamal KJ, Tolstrup JS, Friberg J, Grønbaek M, Jensen G. Fibrinogen and albumin levels and risk of atrial fibrillation in men and women (the Copenhagen City Heart Study). Am J Cardiol. 2006;98:75–81.PubMedCrossRef Mukamal KJ, Tolstrup JS, Friberg J, Grønbaek M, Jensen G. Fibrinogen and albumin levels and risk of atrial fibrillation in men and women (the Copenhagen City Heart Study). Am J Cardiol. 2006;98:75–81.PubMedCrossRef
51.
go back to reference Yi S, Chen M. Decreased albumin is associated with elevated N-terminal pro-brain natriuretic peptide and poor long-term prognosis in patients with chronic heart failure. Medicine (Baltimore). 2020;99:e23872.PubMedCrossRef Yi S, Chen M. Decreased albumin is associated with elevated N-terminal pro-brain natriuretic peptide and poor long-term prognosis in patients with chronic heart failure. Medicine (Baltimore). 2020;99:e23872.PubMedCrossRef
52.
go back to reference Ancion A, Allepaerts S, Oury C, Gori AS, Piérard LA, Lancellotti P. Serum albumin level and hospital mortality in acute non-ischemic heart failure. ESC Heart Fail. 2017;4:138–45.PubMedPubMedCentralCrossRef Ancion A, Allepaerts S, Oury C, Gori AS, Piérard LA, Lancellotti P. Serum albumin level and hospital mortality in acute non-ischemic heart failure. ESC Heart Fail. 2017;4:138–45.PubMedPubMedCentralCrossRef
53.
go back to reference Shimura T, Yamamoto M. Transcatheter aortic valve implantation and frailty. Cardiovasc Interv Ther. 2022;37:626–34.PubMedCrossRef Shimura T, Yamamoto M. Transcatheter aortic valve implantation and frailty. Cardiovasc Interv Ther. 2022;37:626–34.PubMedCrossRef
54.
go back to reference Tan M, Urasawa K, Haraguchi T, et al. Mortality risk after use of a paclitaxel-coated stent in femoropopliteal peripheral artery disease. Cardiovasc Interv Ther. 2022;37:136–44.PubMedCrossRef Tan M, Urasawa K, Haraguchi T, et al. Mortality risk after use of a paclitaxel-coated stent in femoropopliteal peripheral artery disease. Cardiovasc Interv Ther. 2022;37:136–44.PubMedCrossRef
55.
go back to reference Wada H, Dohi T, Miyauchi K, et al. Long-term clinical impact of serum albumin in coronary artery disease patients with preserved renal function. Nutr Metab Cardiovasc Dis. 2018;28:285–90.PubMedCrossRef Wada H, Dohi T, Miyauchi K, et al. Long-term clinical impact of serum albumin in coronary artery disease patients with preserved renal function. Nutr Metab Cardiovasc Dis. 2018;28:285–90.PubMedCrossRef
56.
go back to reference González-Pacheco H, Amezcua-Guerra LM, Sandoval J, et al. Prognostic implications of serum albumin levels in patients with acute coronary syndromes. Am J Cardiol. 2017;119:951–8.PubMedCrossRef González-Pacheco H, Amezcua-Guerra LM, Sandoval J, et al. Prognostic implications of serum albumin levels in patients with acute coronary syndromes. Am J Cardiol. 2017;119:951–8.PubMedCrossRef
57.
go back to reference Yoshioka G, Tanaka A, Nishihira K, Shibata Y, Node K. Prognostic impact of serum albumin for developing heart failure remotely after acute myocardial infarction. Nutrients. 2020;12:2637.PubMedPubMedCentralCrossRef Yoshioka G, Tanaka A, Nishihira K, Shibata Y, Node K. Prognostic impact of serum albumin for developing heart failure remotely after acute myocardial infarction. Nutrients. 2020;12:2637.PubMedPubMedCentralCrossRef
58.
go back to reference Yoshioka G, Natsuaki M, Goriki Y, et al. Serum albumin and bleeding events after percutaneous coronary intervention in patients with acute myocardial infarction (from the HAGAKURE-ACS Registry). Am J Cardiol. 2022;165:19–26.PubMedCrossRef Yoshioka G, Natsuaki M, Goriki Y, et al. Serum albumin and bleeding events after percutaneous coronary intervention in patients with acute myocardial infarction (from the HAGAKURE-ACS Registry). Am J Cardiol. 2022;165:19–26.PubMedCrossRef
59.
go back to reference Goro Y, Atsushi T, Yuhei G, Koichi N. The role of albumin level in cardiovascular disease: a review of recent research advances. J Lab Precis Med. 2023;8:7–7.CrossRef Goro Y, Atsushi T, Yuhei G, Koichi N. The role of albumin level in cardiovascular disease: a review of recent research advances. J Lab Precis Med. 2023;8:7–7.CrossRef
60.
go back to reference Yoshioka G, Tanaka A, Nishihira K, et al. Prognostic impact of follow-up serum albumin after acute myocardial infarction. ESC Heart Fail. 2021;8:5456–65.PubMedPubMedCentralCrossRef Yoshioka G, Tanaka A, Nishihira K, et al. Prognostic impact of follow-up serum albumin after acute myocardial infarction. ESC Heart Fail. 2021;8:5456–65.PubMedPubMedCentralCrossRef
Metadata
Title
Importance of reassessment to identify trajectories of chronic transition of clinical indicators in post-myocardial infarction management
Authors
Goro Yoshioka
Atsushi Tanaka
Shinjo Sonoda
Tetsuya Kaneko
Hiroshi Hongo
Kensuke Yokoi
Masahiro Natsuaki
Koichi Node
Publication date
14-04-2024
Publisher
Springer Nature Singapore
Published in
Cardiovascular Intervention and Therapeutics
Print ISSN: 1868-4300
Electronic ISSN: 1868-4297
DOI
https://doi.org/10.1007/s12928-024-01000-w